164 Boys for Hypospadias Surgery Under General Anesthesia With Caudal BlockNCT03791879
Caudal Dexmedetomidine Analgesia in Pediatrics .
A study testing Caudal dexamedatomidine analgesia in people with 164 Boys for Hypospadias Surgery Under General Anesthesia With Caudal Block, run by Mansoura University at 1 site in Egypt.
Trial summary
Dexmedetomidine (DEXM) is a highly selective α2-adrenoceptor agonist that has been used increasingly in pediatric anesthesia. This prospective double blinded randomized comparative study is designed to evaluate the analgesic effect of caudal increasing doses of DEXM 0.5 , 1 , 1.5 , 2µg/kg combined with Levobupivacaine… Read more about this study
- Who is it for?
- Ages 1 year to 8 years, men only
- Conditions the study is for
- 164 Boys for Hypospadias Surgery Under General Anesthesia With Caudal Block
- What is being tested?
- Caudal dexamedatomidine analgesia
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 164 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jan 2019to 15 Oct 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 8 years
- Men only
- No healthy volunteers
- Child
Who may be able to join
- 164 boys (age 1-8 years, ASA I) scheduled for hypospadias surgery
Who cannot join
- Operative time exceeding 3 hours, bodyweight >25kg, bleeding diathesis, infection at the site of block, pre-existing neurological or spinal disease or abnormalities of the sacrum, inability to palpate the sacral hiatus by anatomic landmark palpation technique) or those with a history of allergic reactions to local anesthetics were excluded from the study
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Anesthesia department,Faculty of medicine, Mansoura univerisety
Al Mansurah
About this study
Official title: The Analgesic Effectiveness and Safety of Upgraded Caudal Dexmedetomidine Doses in Pediatric Hypospadias Surgery.
Dexmedetomidine (DEXM) is a highly selective α2-adrenoceptor agonist that has been used increasingly in pediatric anesthesia. This prospective double blinded randomized comparative study is designed to evaluate the analgesic effect of caudal increasing doses of DEXM 0.5 , 1 , 1.5 , 2µg/kg combined with Levobupivacaine (Levob) 0.125% (ED95% =125%=least effective concentration) in providing pain relief over a 24-h period and lowest surgical stress peak. Study hypothesis: Levobupivacaine 0.125 %( ED95) combined with different increasing doses of dexamedatomedine >1 µg/kg could not add more analgesic \& stress response obtundation outcome, but increase side effects (sedation and hemodynamic depression). The peak cortisol level during urology surgery was at the end of the 1st postoperative (PO) hour. Aim of the Study: To detect the optimal analgesic and safe caudal adjuvant DEXM dose associated with the least side effects\& stress response modulation, guided by PO Cortisol peak difference in between the study groups during pediatric hypospadias surgery.
Read the detailed description
Background: Dexmedetomidine (DEXM) is a highly selective α2-adrenoceptor agonist that has been used increasingly in pediatric anesthesia. This prospective double blinded randomized comparative study is designed to evaluate the analgesic effect of caudal increasing doses of DEXM 0.5 , 1 , 1.5 , 2µg/kg combined with Levobupivacaine (Levob) 0.125% (ED95% =125%=least effective concentration) in providing pain relief over a 24-h period and lowest surgical stress peak. Study hypothesis: Levobupivacaine 0.125 %( ED95) combined with different increasing doses of dexamedatomedine >1 µg/kg could not add more analgesic \& stress response obtundation outcome, but increase side effects (sedation and hemodynamic depression).The peak cortisol level during urology surgery was at the end of the 1st postoperative (PO) hour. Aim of the Study: To detect the optimal analgesic and safe caudal adjuvant DEXM dose associated with the least side effects\& stress response modulation, guided by PO Cortisol peak difference in between the study groups during pediatric hypospadias surgery.
Optimal effective dose defined as; the least caudal DEXM dose which produce the best analgesic outcome [least time to 1st analgesic request and lowest rescue analgesic dose (24Hs)] associated with the least stress response (cortisol PO. first One hour peak), least PO sedation, and hemodynamic stability IO. \&PO. HR \& MAP. The peak cortisol level during urology surgery was at the end of the 1st postoperative (PO) hour.
. Material \& Methods A prospective randomized double blinded (drug injector and PO assessor) comparative study will be conducted in Mansoura university hospital after obtaining ethics committee approval and written informed parental consent 164 boys (age 1-6 years, ASA I) scheduled for hypospadias surgery. Exclusion criteria; (Operative time exceeding 3 hours, bodyweight >25kg, bleeding diathesis, infection at the site of block, pre-existing neurological or spinal disease or abnormalities of the sacrum, inability to palpate the sacral hiatus by anatomic landmark palpation technique) or those with a history of allergic reactions to local anesthetics were excluded from the study. Patients will fast for solids 6h and water and 2 hours before surgery. After Patient Preoperative preparation, General anesthesia induction, caudal block and caudal drug injection (Levob plus DEXM) bolus will be injected according to each group as follow;
- Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/kg.
- Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg.
- Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/kg.
- Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg.
The study outcomes recording:
1ry outcome: Time to (1st analgesic request OPS >4). Secondary outcome: Total 24hours PO. Rescue analgesic dose IM pethidine 0.5mg/kg [2,3] based on local policy and protocol, Patients demographic data [age, weight, end tidal Sevoflurane (volume %) prior starting skin closure, intraoperative fentanyl total dose, recovery time (time from discontinuation of anesthesia to spontaneous eye opening)], Serum Cortisol level at basal before anesthesia and 1hour postoperative in between groups [1] , Apnea incidence (NO\&%), and desaturation (NO\&%), Objective pain score, Sedation score, Behavioral score for Agitation assessment, and Modified bromage score (residual Lower limb muscle weakness) recorded every 15 minutes for 1st hour then every 30 minutes for next 3 PO hours then at next 6th, 12th, 18th, 24th PO hours, hemodynamics, HR\&SBP the incidence of bradycardia and hypotension per 50% percentile. Recorded every 10 minutes IO for maximum operative time 3 hours and every 30 min PO for next 2h in the recovery room until the child was discharged to the ward.
- Being tested
- Caudal dexamedatomidine analgesia
- Keywords
- Caudal, Dexmedetomidine, Levobupivacaine, hypospadias
- Medical subject headings
- Hypospadias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Caudal dexamedatomidine analgesiaDrug
Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.
After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg.
| Study group | Role | What they receive |
|---|---|---|
| • Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k | Active comparator | Not described Receives: Drug: Caudal dexamedatomidine analgesia |
| • Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg. | Active comparator | Not described Receives: Drug: Caudal dexamedatomidine analgesia |
| • Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/ | Active comparator | Not described Receives: Drug: Caudal dexamedatomidine analgesia |
| • Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg. | Active comparator | Not described Receives: Drug: Caudal dexamedatomidine analgesia |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to (1st analgesic request objective pain score (OPS) ≥4)
time from full recovery till child express moderate pain OPS 4 and ask for the first analgesic dose
Measured: Basal (0) till 24 hours.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jan 2019
- Study start1 Jan 2019
- Primary completion1 Oct 2020
- Study completion15 Oct 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for 164 Boys for Hypospadias Surgery Under General Anesthesia With Caudal BlockStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 164 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Abd Latif Ghanim, Mansoura University
- Investigators
- mohamed A Ghanem, A professor, Study chair, Mansoura Univeristy
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03791879
- Sponsor's protocol ID
- MFM IR.18.11.322 - 2018/11/11
- Status last verified
- Feb 2021
- First submitted
- 29 Dec 2018
- Last updated
- 1 Mar 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Analgesic Effectiveness and Safety of Upgraded Caudal Dexmedetomidine Doses in Pediatric Hypospadias Surgery.
- ClinicalTrials.gov ID
- NCT03791879
- Acronym / sponsor ID
- MFM IR.18.11.322 - 2018/11/11
- Keywords
- Caudal, Dexmedetomidine, Levobupivacaine, hypospadias
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 164 participants (actual)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- 1 Oct 2020 (actual)
- Study completion
- 15 Oct 2020 (actual)
- First posted
- 3 Jan 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dexmedetomidine (DEXM) is a highly selective α2-adrenoceptor agonist that has been used increasingly in pediatric anesthesia. This prospective double blinded randomized comparative study is designed to evaluate the analgesic effect of caudal increasing doses of DEXM 0.5 , 1 , 1.5 , 2µg/kg combined with Levobupivacaine (Levob) 0.125% (ED95% =125%=least effective concentration) in providing pain relief over a 24-h period and lowest surgical stress peak. Study hypothesis: Levobupivacaine 0.125 %( ED95) combined with different increasing doses of dexamedatomedine >1 µg/kg could not add more analgesic \& stress response obtundation outcome, but increase side effects (sedation and hemodynamic depression). The peak cortisol level during urology surgery was at the end of the 1st postoperative (PO) hour. Aim of the Study: To detect the optimal analgesic and safe caudal adjuvant DEXM dose associated with the least side effects\& stress response modulation, guided by PO Cortisol peak difference in between the study groups during pediatric hypospadias surgery.
Detailed description
Background: Dexmedetomidine (DEXM) is a highly selective α2-adrenoceptor agonist that has been used increasingly in pediatric anesthesia. This prospective double blinded randomized comparative study is designed to evaluate the analgesic effect of caudal increasing doses of DEXM 0.5 , 1 , 1.5 , 2µg/kg combined with Levobupivacaine (Levob) 0.125% (ED95% =125%=least effective concentration) in providing pain relief over a 24-h period and lowest surgical stress peak. Study hypothesis: Levobupivacaine 0.125 %( ED95) combined with different increasing doses of dexamedatomedine >1 µg/kg could not add more analgesic \& stress response obtundation outcome, but increase side effects (sedation and hemodynamic depression).The peak cortisol level during urology surgery was at the end of the 1st postoperative (PO) hour. Aim of the Study: To detect the optimal analgesic and safe caudal adjuvant DEXM dose associated with the least side effects\& stress response modulation, guided by PO Cortisol peak difference in between the study groups during pediatric hypospadias surgery.
Optimal effective dose defined as; the least caudal DEXM dose which produce the best analgesic outcome [least time to 1st analgesic request and lowest rescue analgesic dose (24Hs)] associated with the least stress response (cortisol PO. first One hour peak), least PO sedation, and hemodynamic stability IO. \&PO. HR \& MAP. The peak cortisol level during urology surgery was at the end of the 1st postoperative (PO) hour.
. Material \& Methods A prospective randomized double blinded (drug injector and PO assessor) comparative study will be conducted in Mansoura university hospital after obtaining ethics committee approval and written informed parental consent 164 boys (age 1-6 years, ASA I) scheduled for hypospadias surgery. Exclusion criteria; (Operative time exceeding 3 hours, bodyweight >25kg, bleeding diathesis, infection at the site of block, pre-existing neurological or spinal disease or abnormalities of the sacrum, inability to palpate the sacral hiatus by anatomic landmark palpation technique) or those with a history of allergic reactions to local anesthetics were excluded from the study. Patients will fast for solids 6h and water and 2 hours before surgery. After Patient Preoperative preparation, General anesthesia induction, caudal block and caudal drug injection (Levob plus DEXM) bolus will be injected according to each group as follow;
- Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/kg.
- Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg.
- Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/kg.
- Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg.
The study outcomes recording:
1ry outcome: Time to (1st analgesic request OPS >4). Secondary outcome: Total 24hours PO. Rescue analgesic dose IM pethidine 0.5mg/kg [2,3] based on local policy and protocol, Patients demographic data [age, weight, end tidal Sevoflurane (volume %) prior starting skin closure, intraoperative fentanyl total dose, recovery time (time from discontinuation of anesthesia to spontaneous eye opening)], Serum Cortisol level at basal before anesthesia and 1hour postoperative in between groups [1] , Apnea incidence (NO\&%), and desaturation (NO\&%), Objective pain score, Sedation score, Behavioral score for Agitation assessment, and Modified bromage score (residual Lower limb muscle weakness) recorded every 15 minutes for 1st hour then every 30 minutes for next 3 PO hours then at next 6th, 12th, 18th, 24th PO hours, hemodynamics, HR\&SBP the incidence of bradycardia and hypotension per 50% percentile. Recorded every 10 minutes IO for maximum operative time 3 hours and every 30 min PO for next 2h in the recovery room until the child was discharged to the ward.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| • Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k | Active comparator | Drug: Caudal dexamedatomidine analgesia |
| • Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg. | Active comparator | Drug: Caudal dexamedatomidine analgesia |
| • Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/ | Active comparator | Drug: Caudal dexamedatomidine analgesia |
| • Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg. | Active comparator | Drug: Caudal dexamedatomidine analgesia |
Who may qualify
- Ages
- 1 year to 8 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- 164 boys (age 1-8 years, ASA I) scheduled for hypospadias surgery
Key exclusion criteria (1 listed)
- Operative time exceeding 3 hours, bodyweight >25kg, bleeding diathesis, infection at the site of block, pre-existing neurological or spinal disease or abnormalities of the sacrum, inability to palpate the sacral hiatus by anatomic landmark palpation technique) or those with a history of allergic reactions to local anesthetics were excluded from the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Caudal dexamedatomidine analgesiaTechnique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22-G short-beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament. After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg. | Drug | • Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k, • Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg., • Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/, • Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg. |
Primary outcome
Time to (1st analgesic request objective pain score (OPS) ≥4)
Time frame: Basal (0) till 24 hours.
time from full recovery till child express moderate pain OPS 4 and ask for the first analgesic dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Mar 2021.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
mohamed A Ghanem, A professor study chair
Mansoura Univeristy
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Caudal dexamedatomidine analgesia in people with 164 Boys for Hypospadias Surgery Under General Anesthesia With Caudal Block, run by Mansoura University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to (1st analgesic request objective pain score (OPS) ≥4) (time frame: Basal (0) till 24 hours.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2021.